Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited is one of India‚Äôs leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are…
What Dr. files
- Others57
- Investor Meet32
- Updates25
- Important18
- Dividend/Bonus18
- Board Meeting14
Dr. Lal Ventures, a subsidiary, completed its 30% stake subscription in Neuome Technologies. Neuome is now an associate company, expanding Dr. Lal PathLabs' strategic reach.
Dr Lal PathLabs' wholly-owned Dubai subsidiary incorporated a new step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan. This expands its diagnostic services, with the subsidiary subscribing to 70% of the new entity's share capital at face value.
Dr Lal PathLabs reported Q1 FY27 revenue of Rs 798 Cr (+19.1%) and PAT of Rs 170 Cr (+27.2%). Declared Rs 5 interim dividend. Strategic acquisitions include 80% of Sunshine Healthcare, Ghana (diagnostic business) and 30% of Neuome Technologies (innovative solutions).
Board approved Q1 results: Revenue INR 797.7 Cr, Profit INR 169.5 Cr. Interim dividend declared at INR 5/share. Acquisitions include SDCPL for INR 20 Cr, 80% of Ghana's SHL for INR 38 Cr, and 30% of Neuome for INR 3.5 Cr.
Lal PathLabs won its Income Tax appeal, securing approval for a ₹32.66 Cr deduction on ESOP expenses. This favorable ruling resolves a previously contested tax assessment.